Navigation Links
Clinical Conductor Site Clinical Trial Management System (CTMS) Improves Clinical Trial Productivity at Research Sites
Date:3/25/2009

ROCHESTER, N.Y., March 25 /PRNewswire/ -- Bio-Optronics, Inc., a leader in healthcare workflow software, announces that its Clinical Conductor Site Clinical Trial Management System (CTMS) continues to improve productivity for investigative clinical research sites, particularly in the areas of patient recruitment, advertising ROI, scheduling, and financial management.

Patient recruitment continues to be an area of concern for clinical trials. Clinical Conductor Site CTMS helps improve recruitment efficiency by providing the tools to leverage existing patient databases, easily track advertising ROI, and implement web-based virtual recruitment. At Rochester Clinical Research, "All aspects of recruiting have changed," states Pat Larrabee, President and CEO. "We target and manage our patient population, and are quicker at identifying patients for studies, even difficult ones." She adds, "Clinical Conductor has changed where we put our advertising dollars. We know what's working and what's not." Other sites parallel this experience and some have even gained additional sponsor funding using metrics on the effectiveness of ads.

Clinical Conductor helps sites improve productivity by centralizing information and providing real-time access from multiple locations. At Clinical Research Advantage, scheduling, study status, staffing, and financial management have become more efficient. Eric Levie, Chief Technology Officer states, "We're able to balance staff load better, budget better, and, with real-time data, have an accurate snapshot of the profitability of a study." He adds, "Previously, we used hundreds of spreadsheets, and it took a great deal of time to gather the information needed for payments. Now, stipend payments are issued with a few clicks, and with QuickBooks integration there's no duplicate entry."

Single-site and multi-site clinical research organizations, and those converting from manual spreads
'/>"/>

SOURCE Bio-Optronics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. CareTech Solutions Launches Robust Service Desk Solution to Support Clinical Applications and Technology within Continuum Health Partners Hospitals
2. Intensive summer program helps physicians build clinical research careers
3. Sound Inpatient Physicians Report on New Clinical Processes to Reduce Healthcare Costs and Enhance Care
4. Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes
5. New Clinical Study News for Treatment of Sinusitis, Sinus Infection and Allergy Sufferers Now Have a New Effective Form of Relief through Sinus Dynamics
6. Herbalife Protein Shake Proven Effective in Clinical Study
7. Latest Osteoporosis Research Translated for Health Professionals to Use in Clinical Setting
8. Former Merck Executive Joins Board of Clinical Information Network, Inc.
9. New Clinical Study News for Treatment of Sinusitis - Sinus Infection and Allergy Suffers Now Have a New Effective Form of Relief through Sinus Dynamics
10. Conflicts of interest in clinical research
11. Smart Phones to be used by assisTek to Collect Patient-Reported Outcomes in a Large Multinational Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... New York (PRWEB) July 26, 2014 ... filed in state and federal litigations since the 2012 ... has surpassed 3,700 filings, Bernstein Liebhard LLP reports. According ... at least 2,064 cases have been filed in the ... Rejuvenate Hip Stem and the ABG II Modular Hip ...
(Date:7/26/2014)... “Today, we introduce our new items ... over the world. All these models are offered at ... the UK market,” says the CEO of the company. ... women’s special occasion outfits. , Ladies have to find ... is one of the best choices for many ladies ...
(Date:7/26/2014)... “BRIC Sinuscopes Market Outlook to 2020,? provides key ... provides value, in millions of US dollars, volume (in ... segments – Rigid Non-Video Sinuscopes. , The report also ... of these market categories, and global corporate-level profiles of ... deals related to the Sinuscopes market wherever available. , ...
(Date:7/26/2014)... According to the Tinnitus ... this is a comprehensive guide that consists ... all types of disorders related to ... due to Ménière's disease ,     Objective ... tinnitus ,     Inner, middle or external ...
(Date:7/26/2014)... New York (PRWEB) July 26, 2014 ... to be filed in U.S. courts, Bernstein Liebhard LLP ... federal health regulators to ban uterine morcellation. According to ... a 46-year-old mother of four from California who was ... cancer called leiomyosarcoma just 10 days after undergoing a ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 3Health News:Famous Supplier DressesOnlineShops.co.uk Announces Its New Selection of Prom Dresses for the UK Market 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 3Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 4Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 4
... of two titles, Journal of Analytical Toxicology ( JAT ... from Preston Publications, in a transaction managed by DeSilva+Phillips. The ... STM journal list published by OUP. "We are ... two titles. They have a rich history and we look forward ...
... HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay News) -- The ... a handy jet at your disposal, but the job also comes ... your life? Maybe not, new research suggests. The data showed ... years off their lives due to the effects of time spent ...
... HOBOKEN, NJ Keeping your brain in shapeno sweat. ... diet is just as important to maintaining mental performance ... are an easy, effective way to manage mental focus, ... antioxidant plant extract from the bark of the French ...
... depressive symptoms following birth also reported intimate partner violence finds ... An International Journal of Obstetrics and Gynaecology . The ... depressive symptoms first reported this at six months after birth ... emotional abuse) in the perinatal period is associated with a ...
... , TUESDAY, Dec. 6 (HealthDay News) -- New ... and when women with certain breast cancers will experience ... forms of breast cancer, are slated to be presented ... The research also revealed that genetic data gleaned ...
... in India are too poor to afford pacemakers. But a ... the devices and implanting them in Indian patients "is very ... Medical Center is a co-author of the study, published online ... . Kulkarni helped conduct the research before coming to Loyola ...
Cached Medicine News:Health News:Oxford University Press acquires 2 journals from Preston Publications 2Health News:Most U.S. Presidents Live Longer Than Their Peers 2Health News:Pycnogenol® found to improve memory and test scores in college students in new clinical trial 2Health News:Depressive symptoms and intimate partner violence in the 12 months after childbirth 2Health News:New Tests Might Better Predict Breast Cancer's Return 2Health News:New Tests Might Better Predict Breast Cancer's Return 3Health News:New Tests Might Better Predict Breast Cancer's Return 4Health News:Reusing pacemakers from deceased patients is safe and effective, study finds 2
(Date:7/25/2014)... , N.Y. and MEXICO CITY , ... today announced that PLM, a Latin American healthcare sciences ... to deliver medical information on conditions such as cancer ... can now access the most up-to-date information to deliver ... medical professionals is growing rapidly, with many relying on ...
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and General ... and Packaging (EMIP) Division. "I am pleased ... management and business development experience, especially in the medical ... contributions to the continued growth and success of our ...
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR ... JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ... ABBV ) today announced financial results for the ... was another very strong quarter for AbbVie, as we delivered ... announced plans to merge with Shire, a strategic action that ...
Breaking Medicine Technology:Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32
... SEATTLE, March 25 Cell Therapeutics, Inc.,(CTI) (Nasdaq: ... complete in,the phase III EXTEND (PIX301) clinical trial of ... non-Hodgkin,s lymphoma (NHL).,An analysis of the data is expected ... with the U.S. Food and Drug Administration (FDA) the ...
... Patients to ... Higher Rates of BARACLUDE Resistance -, PRINCETON, N.J., ... a continued low incidence of,resistance in nucleoside-naive patients through ... patients analyzed, no additional,patient developed resistance in the fifth ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 2Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 3Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 4BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 2BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 3BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 4BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 5BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: